Levetiracetam for Managing Neurologic and Psychiatric Disorders

Muhammad U. Farooq; Archit Bhatt; Arshad Majid; Rishi Gupta; Atul Khasnis; Mounzer Y. Kassab


Am J Health Syst Pharm. 2009;66(6):541-561. 

In This Article

Future Directions

Levetiracetam is an effective AED for use as an adjunct agent in partial-onset and generalized seizures in adults and myoclonic epilepsy in adolescents (≥ 12 years of age) and adults. The data about its use in non-epileptic disorders are emerging. An open-label, Phase II clinical trial is under way to evaluate the possible efficacy and safety of levetiracetam for spasticity and cramps related to amyotrophic lateral sclerosis.[109] However, most of the current data about the role of levetiracetam in nonepileptic conditions lack large sample sizes and long-term longitudinal efficacy and safety in these nonepileptic conditions. Therefore, the role of levetiracetam in these nonepileptic conditions needs to be elucidated more comprehensively. Levetiracetam's exact place in the treatment of individual disorders warrants further clarification. Further open-label trials evaluating its efficacy and safety in different nonepileptic disorders are under way. Future trials will continue to shed light on the best indications for levetiracetam. Long-term data on adverse reactions will also continue to emerge in parallel.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.